Vertical Transmission of Babesia microti, United States

Julie T. Joseph, Kerry Purtill, Susan J. Wong, Jose Munoz, Allen Teal, Susan Madison-Antenucci, Harold W. Horowitz, Maria E. Aguero-Rosenfeld, Julie M. Moore, Carlos Abramowsky, and Gary P. Wormser

Babesiosis is usually acquired from a tick bite or through a blood transfusion. We report a case of babesiosis in an infant for whom vertical transmission was suggested by evidence of Babesia spp. antibodies in the heel-stick blood sample and confirmed by detection of Babesia spp. DNA in placenta tissue.

Babesiosis is an emerging infection in the United States, principally caused by Babesia microti (1). The most common route of infection is the bite of an Ixodes scapularis tick; transmission can also occur by transfusion of infected blood products, and vertical transmission in animals has been documented (2,3) and is a potential route of transmission for humans. We report a case of babesiosis in an infant for whom vertical transmission was suggested by Babesia spp. antibodies in a heel spot blood sample and confirmed by detection of Babesia DNA in placenta tissue.

The Case-Patient
A 6-week-old girl from Yorktown Heights, New York, was admitted to the hospital on September 16, 2002, with a 2-day history of fever, irritability, and decreased oral intake. The mother was asymptomatic during and after her pregnancy. The infant was delivered vaginally and full term at 3,430 g without complications. The infant’s mother had visited parks in Westchester and Dutchess Counties in New York during the pregnancy but was unaware of any tick bites. The infant had no known tick exposure, and neither mother nor infant had a history of blood transfusion.

During examination, the infant was alert but irritable and pale. Axillary temperature was initially 36.8°C but increased to 38.1°C on the same day. Her conjunctivae were icteric, she had a palpable spleen tip, and her liver was palpable 3 cm below the costal margin. Initial laboratory findings included hemoglobin 7.1 g/dL, platelet count 100 × 10^3/μL, and leukocyte count 19.7 × 10^3 cells/μL with a differential of 4% segmented neutrophils, 80% lymphocytes, and 16% monocytes. Reticulocyte count was 5.5%. Total bilirubin concentration was 2 mg/dL with a direct fraction of 0.4 mg/dL; aspartate aminotransferase level was 66 U/L, alanine aminotransferase level was 50 U/L, and alkaline phosphatase level was 339 U/L. Cultures of blood, urine, and cerebrospinal fluid samples yielded negative results. Lyme disease serologic test result was negative.

Routine examination of a peripheral blood smear showed B. microti in 4% of erythrocytes (Figure); a blood sample from the infant was positive by PCR for B. microti DNA. Total B. microti antibody titer was >256 by indirect immunofluorescence assay, with a polyvalent secondary antibody (anti-IgG+IgA+IgM) (4) that was presumed to be principally IgG because test results for IgM were negative (online Technical Appendix, wwwnc.cdc.gov/EID/pdfs/11-0988-Techapp.pdf). The heel-stick blood sample obtained on the infant’s third day of life as part of newborn screening was tested and found to be negative for B. microti by PCR (5) and for IgM but total antibody positive (>128) (online Technical Appendix).

Examination of the placenta showed focal basal decidual inflammation, mild chorangiosis, and villus dysmaturity. Babesia spp. piroplasms were not detected in...
maternal or fetal blood by histologic examination of hematoyxlin and eosin–stained sections of formalin-fixed, paraffin-embedded tissue of the placenta disk, amnion/chorion, and umbilical cord. Babesia DNA was detected by real-time PCR testing of paraffin-embedded placenta tissue (online Technical Appendix) (6). Cycle threshold values were relatively high (37.1–38.2), indicating that the amount of parasite DNA in the sample was close to the limit of detection; results were reproducible on duplicate testing of DNA samples extracted from separate paraffin blocks. The real-time PCR product was of the correct size, and the melting curve demonstrated melting temperatures within 1°C from the placenta, the positive control, and a positive sample from an unrelated patient, confirming that the correct product was amplified. At time of the illness in the infant, the mother was negative for Babesia spp. according to PCR and smear but positive for total antibodies (>256).

**Table. Comparison of selected clinical and laboratory data from reported cases of congenital babesiosis in 5 infants**

<table>
<thead>
<tr>
<th>Clinical data</th>
<th>Reference</th>
<th>This study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year of diagnosis/location</td>
<td>Not given/Long Island, New York</td>
<td>Not given/Long Island, New York</td>
</tr>
<tr>
<td>Infant age at time of symptom onset, d</td>
<td>30</td>
<td>32</td>
</tr>
<tr>
<td>Clinical findings</td>
<td>Fever, irritability, pallor, hepatosplenomegaly</td>
<td>Fever, lethargy, poor feeding, pallor, scleral icterus, hepatomegaly</td>
</tr>
<tr>
<td>Initial babesia parasitemia level, %</td>
<td>5</td>
<td>4.4</td>
</tr>
<tr>
<td>Hospitalization, d</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Maternal tick bite</td>
<td>1 wk before delivery</td>
<td>7 wk before delivery</td>
</tr>
<tr>
<td>Babesia spp. serologic and PCR results for infant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Babesia spp. evaluation results for mother</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HGB, g/dL</td>
<td>9.3</td>
<td>10.8</td>
</tr>
<tr>
<td>Platelets, x 10^3/µL</td>
<td>38</td>
<td>87</td>
</tr>
<tr>
<td>Leukocytes/PMN, cells/µL</td>
<td>6,500/1,170</td>
<td>NA</td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>894</td>
<td>NA</td>
</tr>
<tr>
<td>Bilirubin indirect, mg/dL</td>
<td>3.6</td>
<td>9.7</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>90</td>
<td>NA</td>
</tr>
<tr>
<td>ALT, U/L</td>
<td>90</td>
<td>NA</td>
</tr>
<tr>
<td>Treatment</td>
<td>CLI and quinine for 10 d</td>
<td>CLI and quinine with AZT added on day 3, on day 5 changed to AZT plus quinine for additional 7 d</td>
</tr>
<tr>
<td>Follow-up</td>
<td>Well at 6 mo posttreatment</td>
<td>Improved at 2 wk</td>
</tr>
<tr>
<td>Blood transfusion for anemia</td>
<td>Yes, for HCT of 18%</td>
<td>Yes, for HGB of 7.3 g/dL</td>
</tr>
</tbody>
</table>

*No mothers became ill. NA, not available; +, positive; IFA, indirect immunofluorescence assay; ND, not done; -, negative; HGB, hemoglobin; HCT, hematocrit; PMN, polymorphonuclear; LDH, lactate dehydrogenase level; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CLI, clindamycin; AZT, azithromycin; ATO, atovaquone.
The infant was treated with a 9-day course of azithromycin plus atovaquone. A blood transfusion was administered when her hemoglobin concentration fell to 5.2 g/dL. The infant became afebrile by 72 hours and was discharged after a 5-day hospitalization. Repeat blood smears revealed a parasite load of 0.3% at discharge. On final evaluation at 22 months of age, physical examination revealed no abnormalities; hemoglobin level was 11.7 g/dL, *Babesia* PCR was negative, and total *Babesia* antibody level was positive at 128.

**Conclusions**

Congenital babesiosis has been rarely reported (Table (7–10). This case provided convincing evidence for congenital babesiosis because of prepartum infection involving the placenta in the mother. On the basis of experience with congenital malaria, we assume that *Babesia* spp. parasites cross the placenta during pregnancy or at the time of delivery (11,12). In congenital malaria, increasing evidence suggests that the malaria parasites are most often acquired antenatally by transplacental transmission of infected erythrocytes (12).

Reported cases of congenital babesiosis share many similarities, including asymptomatic maternal infection and development of fever, hemolytic anemia, and thrombocytopenia in the infant detected between 19 and 41 days after birth. All of the infants responded to antimicrobial drug therapy; 3 were treated with azithromycin plus atovaquone (9,10), the preferred treatment regimen for mild babesiosis (1). All infants required a blood transfusion because of severe anemia. The clinical signs and symptoms for these cases of congenital babesiosis are similar to those of congenital malaria in non–disease endemic areas (11,13).

We found *Babesia* spp. antibodies on day 3 of life by analyzing the patient’s heel-stick blood sample, which likely represented maternal transfer of IgG. Passive transfer of maternal antibodies is regarded as a protective factor against congenital malaria, and some newborns with malaria who are parasitemic at birth spontaneously clear the infection without ever becoming ill (11,14). The temporary presence of maternal IgG in infants has been suggested as an explanation for the typical 3–6 week incubation period of congenital malaria in non–disease endemic areas (14).

The real-time PCR used to find *B. microti* DNA in placenta tissue is ≈20× more sensitive than microscopic examination of Giemsa-stained blood smears (6). Assuming a blood sample with a parasitemia equivalent to that detected in the placental tissue, a blood smear would contain ≤10 infected cells per slide. Given the low level of *Babesia* DNA in the placenta tissue, it is not surprising that histologic examination did not reveal piroplasms. Nonetheless, limited evidence of placental abnormalities suggests a pathologic process.

In summary, babesiosis is an emerging infectious disease (15) that can rarely cause congenital infection. This diagnosis should be considered in the differential diagnosis of fever and hemolytic anemia in infants from disease-endemic areas.

**Acknowledgments**

The authors thank Steven Smith, Jennifer Calder, Lisa Giarratano, Lenise Banwarie, Ewa Bajor-Dattilo, and Karen Kulas for their assistance.

Dr Joseph is an assistant professor of medicine in the Division of Infectious Diseases at New York Medical College. Her research interests are tick-borne illnesses, particularly babesiosis.

**References**


Address for correspondence: Julie T. Joseph, New York Medical College, Division of Infectious Diseases, Munger Pavilion Room 245, Valhalla, NY 10595, USA; email: julie_joseph@nymc.edu

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the US Department of Health and Human Services.
Vertical Transmission of *Babesia microti*, United States

Technical Appendix

Antibody testing of the infant’s blood spot

Approximately one-fourth of the blood spot (three 1/8 inch diameter punches) was eluted in 140 μL of 10 g/L goat serum (Sigma) in PBS overnight at 4°C. The eluate was filtered through a 0.45-μm syringe filter and then tested in a polyvalent (IgM, IgA, IgG) indirect immunofluorescence assay (IFA) for *Babesia* spp. antibodies. Controls were made by spotting both *Babesia* antibody negative whole blood and the same blood spiked with a positive control serum. The spots were allowed to dry overnight and eluted as above. The IFA used *Babesia* spp.–infected golden hamster erythrocytes fixed to glass slides. The conjugate was polyvalent FITC-conjugated anti-human antibody (Kirkegaard & Perry Laboratories, Gaithersburg, MD) in 0.1% Evans blue dye (1). For detection of IgM antibody specifically, the eluates were treated with Gullsorb (Meridian Diagnostics, now Meridian Bioscience, Cincinnati, OH) to remove IgG and then retested using the same IFA procedure with an IgM-specific FITC-conjugate (KPL). The controls achieved the expected results.

DNA extraction and conventional PCR

DNA was extracted from EDTA-preserved whole blood, 3 mm diameter punches of the dried blood spot, and from freshly cut 10-μm sections of paraffin-embedded tissue, using protocols for blood, dried blood spots, and FFPE Tissue respectively (QIAGEN). Conventional PCR was performed on the extracts from the blood spot and whole blood specimen essentially as previously described targeting the 18S rDNA of *B. microti* (2), except the primer sets were used independently to produce two amplification products. Amplification of the human β-globin gene was performed to test for inhibition. The positive control was a plasmid containing the rDNA target, spiked into a negative blood sample and extracted in parallel with the patient specimen.
Cycling conditions were: 95°C 10 min, 35 cycles (94°C 1 min, 58°C 1 min, 72°C 1 min), with a final extension at 72°C for 4 min.

**Real-Time PCR**

DNA extracted from the paraffin embedded tissue was assayed for the presence of *B. microti* using a recently developed real-time PCR assay targeting the 18S rRNA gene (6). Extracted DNA (15 µl) was amplified using FastStart DNA Master mix without ROX (Roche) in a 25 µl reaction mixture with 5.5 mM MgCl2, 500 nM primers (forward-CAGGGAGGTAGTGACAAGAAATAACA and reverse-GGTGGATTCCATCATTTCCAAT, and 250 nM probe (6FAM-TACAGGGCTTAAAGTC-T-MGBNFQ). A 2-step PCR cycling protocol (95°C 10 min, and 45 cycles of 95°C 15 s, 60°C 1 min) was used to amplify a 72-bp product. An internal control was used to evaluate the efficiency of extraction and test for inhibition of the sample, as described elsewhere (3).

**References**

